Growing a circular economy with fungal biotechnology

August 17, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct
opportunities for tackling the urgent challenges before all humans.

Spotlight

POXEL

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development.

OTHER WHITEPAPERS

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

BLOCKCHAIN ENABLED GENOME SECURITY FROM THE MOMENT IT IS SEQUENCED

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.